Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise
Tirzepatide Showed Superiority To Ozempic In Clinical Trials
The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade.
